Vasoflux
prepared by depolymerization of heparin, restricting molecular size to 3-8 kDa & reducing antithrombin affinity by periodate oxidation; inactivates fibrin-bound thrombin & attenuates factor Xa generation
Networked: 1
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
| 1. | Anderson, H V:
1 article
(08/2001)
|
| 2. | Gibson, M:
1 article
(08/2001)
|
| 3. | Hirsh, J:
1 article
(08/2001)
|
| 4. | Molhoek, P G:
1 article
(08/2001)
|
| 5. | Peters, R J:
1 article
(08/2001)
|
| 6. | Spickler, W:
1 article
(08/2001)
|
| 7. | Théroux, P:
1 article
(08/2001)
|
| 8. | Weaver, W D:
1 article
(08/2001)
|
| 9. | Weitz, J I:
1 article
(08/2001)
|
| 10. | White, H:
1 article
(08/2001)
|
Related Diseases
| 1. | Hemorrhage
|
| 2. | Myocardial Infarction
08/01/2001
- " We randomized 277 patients with acute myocardial infarction to standard intravenous unfractionated heparin (UFH) or intravenous vasoflux 1, 4, 8, or 16 mg/kg as a bolus followed by 1, 4, 8, or 16 mg/kg per hour infusion, on top of streptokinase and aspirin, until angiography at 90 minutes. " 08/01/2001
- " Randomized comparison of a novel anticoagulant, vasoflux, and heparin as adjunctive therapy to streptokinase for acute myocardial infarction: results of the VITAL study (Vasoflux International Trial for Acute Myocardial Infarction Lysis)." 08/01/2001
- " Vasoflux is a low-molecular-weight heparin derivative that inhibits factor IXa activation of factor X and catalyzes fibrin-bound thrombin inactivation by heparin cofactor II. We studied whether vasoflux improves the results of thrombolysis with streptokinase for acute myocardial infarction. "
|
|
Related Drugs and Biologics
Related Therapies and Procedures